Mobilan (M-VM3)
Sponsors
Panacela Labs LLC
Conditions
Prostate Cancer
Phase 1
Safety and Tolerability Clinical Trial of Different Doses of the Immunotherapeutic Drug Mobilan (M-VM3) and Placebo in Patients With Prostate Cancer
CompletedNCT02654938
Start: 2015-07-31End: 2017-09-30Updated: 2017-09-20
A Multicenter Randomized Double-blind Placebo-controlled Pilot Study of Safety, Pharmacodynamics and Efficacy of Different Treatments of Immunotherapeutic Drug Mobilan (M-VM3) in Patients With Diagnosed Prostate Cancer
NCT02844699
Start: 2016-07-31End: 2018-01-31Target: 24Updated: 2017-09-20